GlassScriptPhysician profile
Diane Carol West
NPI 1861488256
$2,802.79
in general payments reported to CMS, 2019-2025
29 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $416 · 2021: $388 · 2022: $374 · 2023: $307 · 2024: $368 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748 · Grant: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.71 |
| Grant | $113.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $394.39 | 2019-2021 | |
| Boston Scientific Corporation | $293.03 | 2019-2025 | Spaceoar Vue System - 10ml |
| Axonics, INC. | $264.03 | 2022-2024 | Axonics, Bulkamid |
| Kerecis Limited | $224.02 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Abbvie INC. | $187.81 | 2020-2023 | Lupron Depot |
| Agiliti Surgical, INC. | $161.25 | 2019 | |
| Janssen Biotech, INC. | $130.30 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $119.02 | 2020 | |
| Dendreon Pharmaceuticals LLC | $111.42 | 2019-2022 | |
| Olympus America INC. | $104.65 | 2024-2025 | Itind System |
| Ferring Pharmaceuticals INC. | $98.48 | 2019 | |
| Myovant Sciences INC. | $93.31 | 2021-2022 | |
| Urogen Pharma, INC. | $76.72 | 2022-2023 | Jelmyto |
| Blue Earth Diagnostics | $74.38 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.98 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $46.01 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $45.99 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $45.06 | 2020-2021 | |
| Urovant Sciences INC | $41.83 | 2022 | |
| Allergan, INC. | $39.79 | 2019-2020 | |
| Genzyme Corporation | $37.45 | 2019 | |
| Sun Pharmaceutical Industries INC. | $33.14 | 2019 | |
| Merck Sharp & Dohme LLC | $23.73 | 2021 | |
| Neotract INC. | $19.15 | 2020 | |
| Travere Therapeutics, INC. | $18.83 | 2019 | |
| Sumitomo Pharma America, INC. | $16.59 | 2023 | Orgovyx |
| Therapeuticsmd, INC. | $16.48 | 2019 | |
| Foundation Medicine, INC. | $14.66 | 2020 | |
| Antares Pharma, INC. | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.